Javascript must be enabled to continue!
HER2 Amplification in Hydatidiform mole patients
View through CrossRef
Hydatidiform mole is an abnormal pregnancy in which the placenta contains grape cell like vesicles (small sacs) , that are usually visible with the naked eye .Patients and methods : This study was carried out in Laboratories of College of Science, Wasit University , AL Zahraa and AL Karma Teaching Hospitals, from October 2014 to April 2015. The study included twenty Hydatidiform mole patients were taken randomly, and six non hydatidiform mole patients as control group. The patients with HM included 10 samples of complete H mole , and 10 samples of partial H mole. Chromogenic In Situ Hybridization (CISH) technique was used to detect the amplification of HER2 gene.Results: Regarding the HER2 amplification (over-expression of HER2) was significantly more frequent in H mole patients than in control (p≤0.05), also the same difference was indicated between complete H mole and control group. As well as between partial H mole and control group . While, HER2 amplification did not differ between complete H mole and partial H mole (p≤0.05) .
Title: HER2 Amplification in Hydatidiform mole patients
Description:
Hydatidiform mole is an abnormal pregnancy in which the placenta contains grape cell like vesicles (small sacs) , that are usually visible with the naked eye .
Patients and methods : This study was carried out in Laboratories of College of Science, Wasit University , AL Zahraa and AL Karma Teaching Hospitals, from October 2014 to April 2015.
The study included twenty Hydatidiform mole patients were taken randomly, and six non hydatidiform mole patients as control group.
The patients with HM included 10 samples of complete H mole , and 10 samples of partial H mole.
Chromogenic In Situ Hybridization (CISH) technique was used to detect the amplification of HER2 gene.
Results: Regarding the HER2 amplification (over-expression of HER2) was significantly more frequent in H mole patients than in control (p≤0.
05), also the same difference was indicated between complete H mole and control group.
As well as between partial H mole and control group .
While, HER2 amplification did not differ between complete H mole and partial H mole (p≤0.
05) .
Related Results
HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and Outcome
HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and Outcome
Abstract
Aims
Apocrine carcinoma of the breast (APO) expresses HER2 in 30-50% of cases. This study explored the clinicopathological features and outcome of HER2+ APO (HER2...
Abstract P3-09-02: The HER2 –positive subtypes by stage and race/ethnicity
Abstract P3-09-02: The HER2 –positive subtypes by stage and race/ethnicity
Abstract
HER2-positivity is often associated with poor survival. The purpose of this study is to determine if there are differences in mortality among the HER-positi...
Abstract 1836: Patient-derived xenograft (PDX) models expressing HER2 reflect clinical responses to targeted HER2 inhibition
Abstract 1836: Patient-derived xenograft (PDX) models expressing HER2 reflect clinical responses to targeted HER2 inhibition
Abstract
Background While HER2-directed agents are most often used for treating breast cancer, there is increasing evidence that these therapies may be of value in o...
Abstract 2271: bcl-2 expression in HER2-positive breast carcinoma subtypes
Abstract 2271: bcl-2 expression in HER2-positive breast carcinoma subtypes
Abstract
Background: HER2-positive breast cancers comprise 20-30% of all breast cancers; amplification of HER2 confers a poorer prognosis. While treatment with anti-...
Human Epidermal Growth Factor Receptor-2(HER-2) expression in Sri Lankan gastric adenocarcinoma patients: An analysis of the concordance of HER2 expression and survival based on silver in-situ hybridization (SISH)
Human Epidermal Growth Factor Receptor-2(HER-2) expression in Sri Lankan gastric adenocarcinoma patients: An analysis of the concordance of HER2 expression and survival based on silver in-situ hybridization (SISH)
Abstract
Background: Accurate HER2 status is crucial for gastric adenocarcinoma (GC) patient selection for antiHER2 therapy. It is assessed immunohistochemically (IHC) for ...
STUDY ON HER2 STATUS AND RELATIONSHIP WITH PROGNOSTIC FACTORS IN INVASIVE BREAST CARCINOMA
STUDY ON HER2 STATUS AND RELATIONSHIP WITH PROGNOSTIC FACTORS IN INVASIVE BREAST CARCINOMA
Background: To select patients with targeted breast cancer need to accurately determine the status of HER2 gene amplification. Therefore, HER2 gene amplification should be determin...
Clinicopathological features and prognosis of patients with HER2-low breast cancer
Clinicopathological features and prognosis of patients with HER2-low breast cancer
Abstract
Background
Low human epidermal growth factor receptor 2 (HER2) expression is an emerging concept in breast cancer that is defined as immunohistochemistry (IHC) 1 ...
A gene expression-based classifier for HER2-low breast cancer
A gene expression-based classifier for HER2-low breast cancer
AbstractIn clinical trials evaluating antibody-conjugated drugs (ADCs), HER2-low breast cancer is defined through protein immunohistochemistry scoring (IHC) 1+ or 2+ without gene a...

